MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)

Progression and treatment rates using an active surveillance protocol incorporating image‐guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable‐risk prostate cancer

“…As our cohort size was relatively small and with a short follow-up, it is perhaps unsurprising that we failed to find many predictors of progression or conversion to treatment. Neither a positive mpMRI lesion nor an initial Grade Group 2 diagnosis predicted progression or conversion to active treatment which is in contrast to other studies [31][32][33]. We did observe that men with a previous negative biopsy appeared less likely to progress, which supports the findings of a recent large Danish study that reported extremely low rates of prostate cancer mortality [0.7-3.6%] from a retrospective database review of men with first negative biopsies over a 20-year follow-up period, underscoring the indolent nature of many of these tumours [34].…”

Updates in prostate cancer detections and treatments – Messages from 2017 EAU and AUA

“…The Kaplan–Meier survival analysis indicated that the 5-year treatment free survival was significantly higher in men without lesions on baseline mpMRI than men with lesions on baseline mpMRI (85.1% vs. 78.3%, p = 0.024). Besides, in patients with Gleason scores of 3 + 3 and 3 + 4, the 5-year treatment free survival was 86.3% and 60.8%, respectively ( p < 0.001) [13] . Above suggested mpMRI could have a role in identifying and assessing targeted patients during AS.…”

“…Retter et al. [13] reported an AS cohort including 387 PCa patients which identified the relationship between mpMRI baselines and the treatment rates in AS. The Kaplan–Meier survival analysis indicated that the 5-year treatment free survival was significantly higher in men without lesions on baseline mpMRI than men with lesions on baseline mpMRI (85.1% vs. 78.3%, p = 0.024).…”